Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

3 recruiting

Enrollment Performance

Analytics

Phase 2
4(100.0%)
4Total
Phase 2(4)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT07538583Phase 2Recruiting

Phase 2/3 Clinical Study of QRX003 Lotion in Subjects With Netherton Syndrome

Role: lead

NCT05521438Phase 2Active Not Recruiting

Safety, Tolerability and Efficacy of QRX003 Lotion in Subjects With Netherton Syndrome

Role: lead

NCT06953466Phase 2Recruiting

Clinical Study of QRX003 Lotion in Subjects With Netherton Syndrome

Role: lead

NCT05789056Phase 2Recruiting

Open Label, Safety and Efficacy Study of QRX003 Lotion in Subjects With Netherton Syndrome

Role: lead

All 4 trials loaded